Warren Olanow News Today : Breaking News, Live Updates & Top

Plaintiffs in Paraquat litigation blame research shortage on Syngenta, EPA; Rosenstengel hears arguments on excluding experts

Published: December 28, 2023

EAST ST. LOUIS - After an expert witness for plaintiffs claiming weed killer paraquat caused Parkinson's disease testified to attributing 74% of the weight of his causation opinion on one study, the plaintiffs explain a shortage of research by accusing manufacturer Syngenta of corrupting science in general and the U.S. Environmental Protection Agency (EPA) in particular.

Source: madisonrecord.com

AskBio to Present Phase 1b Results Investigating AB-1005 (formerly AAV2-GDNF) as Treatment for Parkinson's Disease at AD/PDTM 2023 International Conference on Alzheimer's and Parkinson's Diseases

Published: March 29, 2023

/PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will...

Source: prnewswire.com

NeuroDerm Ltd.: NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations

Published: January 9, 2023

ND0612, a continuous 24 hours/day subcutaneous (SC) infusion?of liquid levodopa/carbidopa (LD/CD), showed superior efficacy compared to oral LD/CD for the primary endpoint ("ON" time without

Source: finanznachrichten.de

Novel Drug Shows Promise as First-Line Parkinson's Treatment

Published: April 11, 2022

An experimental drug that combines low-dose extended-release pramipexole and rasagiline showed strong efficacy in early-stage Parkinson's disease — with less sleepiness — in a new phase 3 trial.

Source: medscape.com

Positive Phase 3 Topline Results for Early Parkinson's Drug

Published: December 27, 2021

The novel drug P2B001 is superior to its individual components of pramipexole or rasagiline for early Parkinson's disease ― with less daytime sleepiness, new topline results suggest.